CoChat

Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations

Díez-Aguilar, María, Morosini, María Isabel, Tedim, Ana P., Rodríguez, Irene, Aktaş, Zerrin, Cantón, Rafael · 2015 · Antimicrobial Agents and Chemotherapy
Cited by 37

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

The antibacterial activity of fosfomycin-tobramycin combination was studied by time-kill assay in eight Pseudomonas aeruginosa clinical isolates belonging to the fosfomycin wild-type population (MIC = 64 μg/ml) but with different tobramycin susceptibilities (MIC range, 1 to 64 μg/ml). The mutant prevention concentration (MPC) and mutant selection window (MSW) were determined in five of these strains (tobramycin MIC range, 1 to 64 μg/ml) in aerobic and anaerobic conditions simulating environments that are present in biofilm-mediated infections. Fosfomycin-tobramycin was synergistic and bactericidal for the isolates with mutations in the mexZ repressor gene, with a tobramycin MIC of 4 μg/ml. This effect was not observed in strains displaying tobramycin MICs of 1 to 2 μg/ml due to the strong bactericidal effect of tobramycin alone. Fosfomycin presented higher MPC values (range, 2,048 to >2,048 μg/ml) in aerobic and anaerobic conditions than did tobramycin (range, 16 to 256 μg/ml). Interestingly, the association rendered narrow or even null MSWs in the two conditions. However, for isolates with high-level tobramycin resistance that harbored aminoglycoside nucleotidyltransferases, time-kill assays showed no synergy, with wide MSWs in the two environments. glpT gene mutations responsible for fosfomycin resistance in P. aeruginosa were determined in fosfomycin-susceptible wild-type strains and mutant derivatives recovered from MPC studies. All mutant derivatives had changes in the GlpT amino acid sequence, which resulted in a truncated permease responsible for fosfomycin resistance. These results suggest that fosfomycin-tobramycin can be an alternative for infections due to P. aeruginosa since it has demonstrated synergistic and bactericidal activity in susceptible isolates and those with low-level tobramycin resistance. It also prevents the emergence of resistant mutants in either aerobic or anaerobic environments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.00822-15

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 30

  1. Morita Y, Tomida J, Kawamura Y. 2014. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol 4:422. · DOI · Paper page
  2. 10.1128/AAC.04238-14 · DOI
  3. 10.1590/0037-8682-0012-2013 · doi:10.1590/0037-8682-0012-2013
  4. 10.1128/AAC.02779-13 · doi:10.1128/aac.02779-13
  5. 10.1111/2049-632X.12015 · DOI
  6. 10.1164/rccm.201105-0924OC · DOI
  7. 10.1128/JB.00748-09 · DOI
  8. 10.1093/jmicro/dfh102 · doi:10.1093/jmicro/dfh102
  9. 10.1128/AAC.05958-11 · doi:10.1128/aac.05958-11
  10. 10.1128/JCM.00753-11 · DOI · Paper page
  11. Gobernado M. 2003. Fosfomicina. Rev Esp Quimioter 16:15–40.
  12. Alvarez F, Olaechea P, Grau S, Marín M, Domínguez A, Martínez-Lanao J, Soy D, Alos M, Victoria M, Sádaba B, Mediavilla A, Fatela D. Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI. Farm Hosp 32:113–123.
  13. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved Standard M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
  14. 10.1371/journal.pone.0069763 · doi:10.1371/journal.pone.0069763
  15. 10.1093/jac/dkg269 · DOI · Paper page
  16. Maciá MD, Borrell N, Pérez JL, Oliver A. 2004. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother 48:7 2665–2672. · DOI
  17. 10.1128/AAC.00148-07 · DOI · Paper page
  18. 10.1128/AAC.47.6.1887-1894.2003 · DOI · Paper page
  19. 10.1128/AAC.43.11.2624 · DOI · Paper page
  20. 10.1016/j.eimc.2010.05.001 · DOI
  21. 10.1126/science.1087619 · DOI · Paper page
  22. 10.1038/35023079 · DOI · Paper page
  23. 10.1016/j.tim.2008.12.003 · DOI · Paper page
  24. 10.1172/JCI0213870 · DOI · Paper page
  25. 10.1128/AAC.00750-13 · DOI
  26. 10.1093/jac/dkp224 · doi:10.1093/jac/dkp224
  27. 10.1016/j.cbi.2004.05.005 · DOI
  28. 10.1128/AAC.01252-13 · DOI · Paper page
  29. 10.1128/AAC.00415-10 · DOI
  30. 10.1111/j.1749-6632.1974.tb43277.x · DOI · Paper page

Cited by

See all 37

Metadata

Authors
Díez-Aguilar, M., Morosini, M. I., Tedim, A. P., Rodríguez, I., Aktaş, Z., & Cantón, R.
Affiliations
  • Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
  • Department of Clinical Microbiology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
Venue
Antimicrobial Agents and Chemotherapy
Published
2015-10
Volume
59
Issue
10
Pages
6039-6045
ISSN
  • 0066-4804
  • 1098-6596
Cited by
37
References
2
Language
en
Licence
journals.asm.org/non-commercial-tdm-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations. https://app.cochat.ai/papers/10.1128/aac.00822-15
The paper
Díez-Aguilar, M., Morosini, M. I., Tedim, A. P., Rodríguez, I., Aktaş, Z., & Cantón, R. (2015). Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00822-15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.